BioCatalyst

Sonrotoclax, Zanubrutinib — catalyst calendar

2 verified catalyst event(s) referencing Sonrotoclax, Zanubrutinib, each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-09-22
in 3mo
ESTIMATED
 READOUT
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Mono
Phase 2 · Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent
 ONC BeOne Medicines Ltd. Sonrotoclax, Zanubrutinib ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
2026-11 (month)
in 4mo
ESTIMATED
 READOUT
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutini
Phase 2 · Chronic Lymphocytic Leukemia
 ONC BeOne Medicines Ltd. Sonrotoclax, Zanubrutinib ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.